13 Jul 2017 --- New data obtained by scientists of the German Centre for Cardiovascular Research (DZHK) provide valuable points of departure for understanding how gut colonization is associated with the development and progress of heart failure. Notably, researchers have found that important groups of bacteria are found less frequently in the gut of patients with heart failure, and the gut flora is not as diverse as in healthy individuals.
The link between heart failure and gut health is well known. The gut has a worse blood supply in instances of heart failure; the intestinal wall is thicker and more permeable, whereby bacteria and bacterial components may find their way into the blood. Moreover, scientists know that the composition of the gut bacteria is altered in other widespread diseases such as type 2 diabetes. Against this backdrop, researchers at the DZHK site Hamburg/Kiel/Lübeck investigated whether and how the gut flora in patients with heart failure changes.
In a project headed by Professor Norbert Frey of the University Hospital Schleswig-Holstein, Campus Kiel, researchers analyzed the gut bacteria in stool samples of healthy inpiduals and patients with heart failure. The study was conducted in close cooperation with Professor Andre Franke’s team at the Christian-Albrechts-Universität zu Kiel, which found that the sections of the bacterial genome deciphered the distinction of the microorganism.
The results showed that a significantly lower proportion of different bacteria are found in the gut in patients with heart failure than in healthy controls. Inpidual important families of bacteria are significantly reduced. It is still unclear whether the gut flora is altered as a result of heart failure or whether it may be a trigger for this disease.
“Of course, other factors also affect the composition of our gut bacteria. We know that the gut flora of a vegan who starts eating meat changes within three days,” explains associate professor Dr. Mark Lüdde of the University Hospital Schleswig-Holstein, Campus Kiel.
For this reason, inpiduals with an extreme diet, such as a vegan diet, were not allowed to participate in the study. Instead, they chose inpiduals with a standard diet comprising both meat and vegetables for both groups, according to Lüdde.
In addition to diet, medication also affects the gut flora. It was, therefore, important that the control group also took medicinal products that patients with heart failure must take routinely. Antibiotics could not have been administered for at least three months prior. Smokers were also included in both groups. All participants were from the same region and were the same age; gender distribution and BMI were equal in both groups.
The observed pattern of the reduced genera and families of bacteria seems very characteristic of heart failure, which is why these results may be new points of departure for therapies. The differences between healthy inpiduals and those with heart failure, thus, came about mainly through the loss of bacteria of the genera Blautia and Collinsella, as well as two previously unknown genera that belong to the families Erysipelotrichaceae and Ruminococcaceae.
Other research projects have shown that the occurrence of Blautia curbs inflammations. Similarly, the genus Faecalibacterium is associated with anti-inflammatory mechanisms. It is, however, not only reduced in patients with heart failure. Since heart failure is accompanied by chronic inflammation, one theory is that the gut flora fosters the systemic inflammation. Scientists currently believe that the gut flora changes as a consequence of heart failure.
Lüdde and his colleagues believe it is plausible that an altered bacterial profile could also be a risk factor or an early disease marker for heart failure. This is supported by the recent characterization of trimethylamine N-oxide (TMAO), a metabolic product of gut bacteria, as an independent risk factor for the mortality rate in patients with heart failure.
14 Nov 2017 –
Researchers have developed recommendations to ...
10 Nov 2017 –
BASF has announced that it has shut down its ...
09 Nov 2017 –
Ajinomoto Co. Inc has acquired an equity ...
08 Nov 2017 –
Frutarom has signed an agreement with AB-Biotics ...
08 Nov 2017 –
MicroBiome Therapeutics, LLC (MBT), a company ...